Neuroinflammation in Alzheimer's disease: Current evidence and future directions

被引:1196
|
作者
Calsolaro, Valeria [1 ]
Edison, Paul [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Neurol Imaging Unit, London SW7 2AZ, England
基金
英国医学研究理事会;
关键词
Alzheimer's; Microglia; Neuroinflammation; Neurodegeneration; Systemic inflammation; PET; RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; POSITRON-EMISSION-TOMOGRAPHY; PERIPHERAL BENZODIAZEPINE-RECEPTOR; MICROGLIAL ACTIVATION; SYSTEMIC INFLAMMATION; CHRONIC NEURODEGENERATION; DOUBLE-BLIND; PARKINSONS-DISEASE;
D O I
10.1016/j.jalz.2016.02.010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Several attempts have been made to treat Alzheimer's disease (AD) using anti-amyloid strategies with disappointing results. It is clear that the "amyloid cascade hypothesis" alone cannot fully explain the neuronal damage in AD, as evidenced both by autopsy and imaging studies. Neuroinflammation plays a significant role in neurodegenerative diseases, whereas the debate is ongoing about its precise role, whether it is protective or harmful. In this review, we focus on the potential mechanism of glial activation and how local and systemic factors influence disease progression. We focus on neuroinflammation in AD, especially in the earliest stages, a vicious cycle of glial priming, release of proinflammatory factors, and neuronal damage. We review the evidence from imaging studies, regarding the temporal relationship between amyloid deposition and neuroinflammation, the influence of systemic inflammation on glial activation, both in acute and chronic stimulation and the relevance of inflammation as a diagnostic and therapeutic target. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:719 / 732
页数:14
相关论文
共 50 条
  • [21] Current and Future Directions for Targeting Lipoxin A4 in Alzheimer's Disease Comment
    Dias, Irundika H. K.
    Griffiths, Helen R.
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 81 (01) : 87 - 90
  • [22] DRUGS IN ALZHEIMER'S DISEASE DEMENTIA: AN OVERVIEW OF CURRENT PHARMACOLOGICAL MANAGEMENT AND FUTURE DIRECTIONS
    Eleti, Saigeet
    PSYCHIATRIA DANUBINA, 2016, 28 : S136 - S140
  • [23] Future directions in animal models of Alzheimer's disease
    Beckman, Danielle
    Baxter, Mark G.
    Morrison, John H.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2018, 96 (12) : 1829 - 1830
  • [24] Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives
    McGrowder, Donovan A.
    Miller, Fabian
    Vaz, Kurt
    Nwokocha, Chukwuemeka
    Wilson-Clarke, Cameil
    Anderson-Cross, Melisa
    Brown, Jabari
    Anderson-Jackson, Lennox
    Williams, Lowen
    Latore, Lyndon
    Thompson, Rory
    Alexander-Lindo, Ruby
    BRAIN SCIENCES, 2021, 11 (02) : 1 - 56
  • [25] Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions
    Larry G Brooks
    David A Loewenstein
    Alzheimer's Research & Therapy, 2
  • [26] Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions
    Brooks, Larry G.
    Loewenstein, David A.
    ALZHEIMERS RESEARCH & THERAPY, 2010, 2 (05)
  • [27] BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
    Moussa-Pacha, Nour M.
    Abdin, Shifaa M.
    Omar, Hany A.
    Alniss, Hasan
    Al-Tel, Taleb H.
    MEDICINAL RESEARCH REVIEWS, 2020, 40 (01) : 339 - 384
  • [28] Traumatic brain injury as a risk factor for Alzheimer's disease: current knowledge and future directions
    Dams-O'Connor, Kristen
    Guetta, Gabrielle
    Hahn-Ketter, Amanda E.
    Fedor, Andrew
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2016, 6 (05) : 417 - 429
  • [29] Anti-inflammatory and immune therapy for Alzheimer's disease: Current status and future directions
    Walker, Douglas
    Lue, Lih-Fen
    CURRENT NEUROPHARMACOLOGY, 2007, 5 (04) : 232 - 243
  • [30] Current Progress and Future Directions in Non-Alzheimer's Disease Tau PET Tracers
    Wongso, Hendris
    Harada, Ryuichi
    Furumoto, Shozo
    ACS CHEMICAL NEUROSCIENCE, 2025, 16 (02): : 111 - 127